The Big Data Dilemma

    A database linking medical history and tissue compound response has direct relevance to future drug discovery projects and healthcare stratification. By making this data available to point-of-care centers, it could transform medication management approaches and improve individual patient care[1]. As the concept of integrating Big Data with healthcare is on the rise, it is increasingly appropriate to have reliable information at your fingertips.

    REPROCELL has initiated a research and development project where historical data regarding Inflammatory Bowel Disease (IBD) has been collated. Tissue samples were donated by patients for whom conservative treatment had failed and subsequently required surgical intervention. This data collection project is in its infancy, but it already includes the anonymized medical history of over 250 different donors.

    Continue reading 

    An Improved Model for IBD Drug Discovery

    Animal models have been used for years to provide proof of concept for new therapies, however there are major flaws which need to be addressed. Studies using mouse models cannot accurately predict patient response to a new compound. Translatability requires a suitable model which will reduce attrition rates in phase II and III clinical trials which are proving to be of detriment to R&D productivity[1].

    Continue reading 

    On the right path to a cure for IBD

    Advances in diagnostics, treatments, and frontiers of research

    In light of World Digestive Disease Day, which is celebrated every year on the 29th of May[1], we will explore the different facets of Inflammatory bowel disease (IBD) and highlight recent advances on the diagnostics, treatments, and the frontiers of research that will one day hopefully provide a cure.

    Continue reading 

    The gut microbiome in health and disease: the future for diagnosis and treatment of IBD and IBS?

    A new method for distinguishing between IBD (inflammatory bowel disease) and IBS (irritable bowel syndrome) could be on the horizon following a publication by researchers from teams in the Netherlands and the US, who profiled the gut microbiome in stool samples from those with IBD, IBS and healthy controls.

    Continue reading